Skip to main content

Advertisement

SpringerLink
Log in

Low-grade glioma in children with neurofibromatosis type 1: surveillance, treatment indications, management, and future directions

  • Research
  • Published:
Child's Nervous System Aims and scope Submit manuscript

Abstract

Neurofibromatosis type 1 (NF1) is an autosomal dominant cancer predisposition syndrome characterized by the development of both central and peripheral nervous system tumors. Low-grade glioma (LGG) is the most prevalent central nervous system tumor occurring in children with NF1, arising most frequently within the optic pathway, followed by the brainstem. Historically, treatment of NF1-LGG has been limited to conventional cytotoxic chemotherapy and surgery. Despite treatment with chemotherapy, a subset of children with NF1-LGG fail initial therapy, have a continued decline in function, or recur. The recent development of several preclinical models has allowed for the identification of novel, molecularly targeted therapies. At present, exploration of these novel precision-based therapies is ongoing in the preclinical setting and through larger, collaborative clinical trials. Herein, we review the approach to surveillance and management of NF1-LGG in children and discuss upcoming novel therapies and treatment protocols.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

Data availability

No datasets were generated or analyzed during the current study.

References

  1. Miller DT, Freedenberg D, Schorry E, Ullrich NJ, Viskochil D, Korf BR (2019) Coucil on genetics; American college of medical genetics and genomics. Health Supervision for Children With Neurofibromatosis Type 1. Pediatrics 143(5):e20190660

    Article  PubMed  Google Scholar 

  2. Koczkowska M, Chen Y, Callens T, Gomes A, Sharp A, Johnson S, Hsiao MC, Chen Z, Balasubramanian M, Barnett CP, Becker TA, Ben-Shachar S, Bertola DR, Blakeley JO, Burkitt-Wright EMM, Callaway A, Crenshaw M, Cunha KS, Cunningham M, D’Agostino MD, Dahan K, De Luca A, Destree A, Dhamija R, Eoli M, Evans DGR, Galvin-Parton P, George-Abraham JK, Gripp KW, Guevara-Campos J, Hanchard NA, Hernandez-Chico C, Immken L, Janssens S, Jones KJ, Keena BA, Kochhar A, Liebelt J, Martir-Negron A, Mahoney MJ, Maystadt I, McDougall C, McEntagart M, Mendelsohn N, Miller DT, Mortier G, Morton J, Pappas J, Plotkin SR, Pond D, Rosenbaum K, Rubin K, Russell L, Rutledge LS, Saletti V, Schonberg R, Schreiber A, Seidel M, Siqveland E, Stockton DW, Trevisson E, Ullrich NJ, Upadhyaya M, van Minkelen R, Verhelst H, Wallace MR, Yap YS, Zackai E, Zonana J, Zurcher V, Claes K, Martin Y, Korf BR, Legius E, Messiaen LM (2018) Genotype-phenotype correlation in NF1: evidence for a more severe phenotype associated with missense mutations affecting NF1 codons 844–848. Am J Hum Genet 102:69–87

    Article  CAS  PubMed  Google Scholar 

  3. Legius E, Messiaen L, Wolkenstein P, Pancza P, Avery RA, Berman Y, Blakeley J, Babovic-Vuksanovic D, Cunha KS, Ferner R, Fisher MJ, Friedman JM, Gutmann DH, Kehrer-Sawatzki H, Korf BR, Mautner VF, Peltonen S, Rauen KA, Riccardi V, Schorry E, Stemmer-Rachamimov A, Stevenson DA, Tadini G, Ullrich NJ, Viskochil D, Wimmer K, Yohay K, International Consensus Group on Neurofibromatosis Diagnostic C, Huson SM, Evans DG, Plotkin SR (2021) Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation. Genet Med 23:1506–1513

    Article  Google Scholar 

  4. Brosius SN, Vossough A, Fisher MJ, Lang SS, Beslow LA, George BJ, Ichord R (2022) Characteristics of moyamoya syndrome in pediatric patients with neurofibromatosis type 1. Pediatr Neurol 134:85–92

    Article  PubMed  Google Scholar 

  5. Kotch C, Brosius SN, De Raedt T, Fisher MJ (2023) Updates in the management of central and peripheral nervous system tumors among patients with neurofibromatosis type 1 and neurofibromatosis type 2. Pediatr Neurosurg 58(5):267–280

    Article  PubMed  Google Scholar 

  6. Costa AA, Gutmann DH (2019) Brain tumors in neurofibromatosis type 1. Neurooncol Adv 1:vdz040

    PubMed  Google Scholar 

  7. Campen CJ, Gutmann DH (2018) Optic pathway gliomas in neurofibromatosis type 1. J Child Neurol 33:73–81

    Article  PubMed  PubMed Central  Google Scholar 

  8. Guillamo JS, Creange A, Kalifa C, Grill J, Rodriguez D, Doz F, Barbarot S, Zerah M, Sanson M, Bastuji-Garin S, Wolkenstein P, Reseau NFF (2003) Prognostic factors of CNS tumours in neurofibromatosis 1 (NF1): a retrospective study of 104 patients. Brain 126:152–160

    Article  PubMed  Google Scholar 

  9. Mahdi J, Shah AC, Sato A, Morris SM, McKinstry RC, Listernick R, Packer RJ, Fisher MJ, Gutmann DH (2017) A multi-institutional study of brainstem gliomas in children with neurofibromatosis type 1. Neurology 88:1584–1589

    Article  PubMed  PubMed Central  Google Scholar 

  10. Parsa CF, Hoyt CS, Lesser RL, Weinstein JM, Strother CM, Muci-Mendoza R, Ramella M, Manor RS, Fletcher WA, Repka MX, Garrity JA, Ebner RN, Monteiro ML, McFadzean RM, Rubtsova IV, Hoyt WF (2001) Spontaneous regression of optic gliomas: thirteen cases documented by serial neuroimaging. Arch Ophthalmol 119:516–529

    Article  CAS  PubMed  Google Scholar 

  11. Packer RJ, Iavarone A, Jones DTW, Blakeley JO, Bouffet E, Fisher MJ, Hwang E, Hawkins C, Kilburn L, MacDonald T, Pfister SM, Rood B, Rodriguez FJ, Tabori U, Ramaswamy V, Zhu Y, Fangusaro J, Johnston SA, Gutmann DH (2020) Implications of new understandings of gliomas in children and adults with NF1: report of a consensus conference. Neuro Oncol 22:773–784

    Article  PubMed  PubMed Central  Google Scholar 

  12. Fisher MJ, Jones DTW, Li Y, Guo X, Sonawane PS, Waanders AJ, Phillips JJ, Weiss WA, Resnick AC, Gosline S, Banerjee J, Guinney J, Gnekow A, Kandels D, Foreman NK, Korshunov A, Ryzhova M, Massimi L, Gururangan S, Kieran MW, Wang Z, Fouladi M, Sato M, Ora I, Holm S, Markham SJ, Beck P, Jager N, Wittmann A, Sommerkamp AC, Sahm F, Pfister SM, Gutmann DH (2021) Integrated molecular and clinical analysis of low-grade gliomas in children with neurofibromatosis type 1 (NF1). Acta Neuropathol 141:605–617

    Article  CAS  PubMed  Google Scholar 

  13. de Blank PMK, Fisher MJ, Liu GT, Gutmann DH, Listernick R, Ferner RE, Avery RA (2017) Optic pathway gliomas in neurofibromatosis type 1: an update: surveillance, treatment indications, and biomarkers of vision. J Neuroophthalmol 37(Suppl 1):S23–S32

    Article  PubMed  PubMed Central  Google Scholar 

  14. Avery RA, Ferner RE, Listernick R, Fisher MJ, Gutmann DH, Liu GT (2012) Visual acuity in children with low grade gliomas of the visual pathway: implications for patient care and clinical research. J Neurooncol 110:1–7

    Article  PubMed  Google Scholar 

  15. Pillay-Smiley N, Leach J, Lane A, Hummel T, Fangusaro J, de Blank P (2023) Evaluating focal areas of signal intensity (FASI) in children with neurofibromatosis type-1 (NF1) treated with selumetinib on Pediatric Brain Tumor Consortium (PBTC)-029B. Cancers (Basel) 15(7):2109

    Article  CAS  PubMed  Google Scholar 

  16. Azizi AA, Walker DA, Liu JF, Sehested A, Jaspan T, Pemp B, Simmons I, Ferner R, Grill J, Hargrave D, Driever PH, Evans DG, Opocher E, Siope Nf1 Opg Nottingham UKW (2021) NF1 optic pathway glioma: analyzing risk factors for visual outcome and indications to treat. Neuro Oncol 23:100–111

    Article  CAS  PubMed  Google Scholar 

  17. Fisher MJ, Loguidice M, Gutmann DH, Listernick R, Ferner RE, Ullrich NJ, Packer RJ, Tabori U, Hoffman RO, Ardern-Holmes SL, Hummel TR, Hargrave DR, Bouffet E, Charrow J, Bilaniuk LT, Balcer LJ, Liu GT (2012) Visual outcomes in children with neurofibromatosis type 1-associated optic pathway glioma following chemotherapy: a multicenter retrospective analysis. Neuro Oncol 14:790–797

    Article  PubMed  PubMed Central  Google Scholar 

  18. Kotch C, Avery R, Getz KD, Bouffet E, de Blank P, Listernick R, Gutmann DH, Bornhorst M, Campen C, Liu GT, Aplenc R, Li Y, Fisher MJ (2022) Risk factors for treatment refractory and relapsed optic pathway glioma in children with neurofibromatosis type 1. Neuro Oncol 24(8):1377–1386

    Article  PubMed  PubMed Central  Google Scholar 

  19. Kotch C, Si SJ, Desai K, Caminada P, Lo Russo FM, Li Y, Liu GT, Avery RA, Fisher MJ (2023) The impact of changes in gadolinium-enhancement on disease progression in children with neurofibromatosis type 1-associated optic pathway glioma: a retrospective analysis. J Neurooncol 164:741–747

    Article  CAS  PubMed  Google Scholar 

  20. Kinori M, Armarnik S, Listernick R, Charrow J, Zeid JL (2021) Neurofibromatosis type 1-associated optic pathway glioma in children: a follow-up of 10 years or more. Am J Ophthalmol 221:91–96

    Article  PubMed  Google Scholar 

  21. Mahdi J, Goyal MS, Griffith J, Morris SM, Gutmann DH (2020) Nonoptic pathway tumors in children with neurofibromatosis type 1. Neurology 95:e1052–e1059

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Henning AM, Handrup MM, Kjeldsen SM, Larsen DA, Ejerskov C (2021) Optic pathway glioma and the sex association in neurofibromatosis type 1: a single-center study. Orphanet J Rare Dis 16:489

    Article  PubMed  PubMed Central  Google Scholar 

  23. Fangusaro J, Witt O, Hernaiz Driever P, Bag AK, de Blank P, Kadom N, Kilburn L, Lober RM, Robison NJ, Fisher MJ, Packer RJ, Young Poussaint T, Papusha L, Avula S, Brandes AA, Bouffet E, Bowers D, Artemov A, Chintagumpala M, Zurakowski D, van den Bent M, Bison B, Yeom KW, Taal W, Warren KE (2020) Response assessment in paediatric low-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group. Lancet Oncol 21:e305–e316

    Article  PubMed  Google Scholar 

  24. Grill J, Laithier V, Rodriguez D, Raquin MA, Pierre-Kahn A, Kalifa C (2000) When do children with optic pathway tumours need treatment? An oncological perspective in 106 patients treated in a single centre. Eur J Pediatr 159:692–696

    Article  CAS  PubMed  Google Scholar 

  25. Dobson V, Quinn GE, Biglan AW, Tung B, Flynn JT, Palmer EA (1990) Acuity card assessment of visual function in the cryotherapy for retinopathy of prematurity trial. Invest Ophthalmol Vis Sci 31:1702–1708

    CAS  PubMed  Google Scholar 

  26. Friedman DS, Katz J, Repka MX, Giordano L, Ibironke J, Hawse P, Tielsch JM (2008) Lack of concordance between fixation preference and HOTV optotype visual acuity in preschool children: the Baltimore Pediatric Eye Disease Study. Ophthalmology 115:1796–1799

    Article  PubMed  Google Scholar 

  27. Fisher MJ, Avery RA, Allen JC, Ardern-Holmes SL, Bilaniuk LT, Ferner RE, Gutmann DH, Listernick R, Martin S, Ullrich NJ, Liu GT (2013) Functional outcome measures for NF1-associated optic pathway glioma clinical trials. Neurology 81:S15–S24

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Avery RA, Mansoor A, Idrees R, Trimboli-Heidler C, Ishikawa H, Packer RJ, Linguraru MG (2016) Optic pathway glioma volume predicts retinal axon degeneration in neurofibromatosis type 1. Neurology 87:2403–2407

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Arnljots U, Nilsson M, Sandvik U, Myrberg IH, Munoz DM, Blomgren K, Hellgren K (2022) Optical coherence tomography identifies visual pathway involvement earlier than visual function tests in children with MRI-verified optic pathway gliomas. Cancers (Basel) 14(2):318

    Article  PubMed  Google Scholar 

  30. de Blank PM, Berman JI, Liu GT, Roberts TP, Fisher MJ (2013) Fractional anisotropy of the optic radiations is associated with visual acuity loss in optic pathway gliomas of neurofibromatosis type 1. Neuro Oncol 15:1088–1095

    Article  PubMed  PubMed Central  Google Scholar 

  31. Hales PW, Smith V, Dhanoa-Hayre D, O’Hare P, Mankad K, d’Arco F, Cooper J, Kaur R, Phipps K, Bowman R, Hargrave D, Clark C (2018) Delineation of the visual pathway in paediatric optic pathway glioma patients using probabilistic tractography, and correlations with visual acuity. Neuroimage Clin 17:541–548

    Article  PubMed  Google Scholar 

  32. Pisapia JM, Akbari H, Rozycki M, Thawani JP, Storm PB, Avery RA, Vossough A, Fisher MJ, Heuer GG, Davatzikos C (2020) Predicting pediatric optic pathway glioma progression using advanced magnetic resonance image analysis and machine learning. Neurooncol Adv 2:vdaa090

    PubMed  PubMed Central  Google Scholar 

  33. Fisher MJ, Liu GT, Ferner RE, Gutmann DH, Listernick R, de Blank P, Zeid J, Ullrich NJ, Heidary G, Bornhorst M, Stasheff SF, Rosser T, Borchert M, Ardern-Holmes S, Flaherty M, Hummel TR, Motley WW, Bielamowicz K, Phillips PH, Bouffet E, Reginald A, Wolf DS, Peragallo J, Van Mater D, El-Dairi M, Sato A, Tarczy-Hornoch K, Klesse L, Hogan N, Foreman N, McCourt E, Allen J, Ranka M, Campen C, Beres S, Moertel C, Areaux R, Stearns D, Orge F, Crawford J, O’Halloran H, Brodsky M, Esbenshade AJ, Donahue S, Cutter G, Avery RA (2020) NFB-09. Enrollment and clinical characteristics of newly diagnosed, neurofibromatosis type 1 associated optic pathway glioma (NF1-OPG): preliminary results from an international multi-center natural history study. Neuro Oncol 22:iii419–iii419

    Article  PubMed Central  Google Scholar 

  34. Carton C, Evans DG, Blanco I, Friedrich RE, Ferner RE, Farschtschi S, Salvador H, Azizi AA, Mautner V, Rohl C, Peltonen S, Stivaros S, Legius E, Oostenbrink R, Group EGNTMG (2023) ERN GENTURIS tumour surveillance guidelines for individuals with neurofibromatosis type 1. EClinicalMedicine 56:101818

    Article  Google Scholar 

  35. Habiby R, Silverman B, Listernick R, Charrow J (1995) Precocious puberty in children with neurofibromatosis type 1. J Pediatr 126:364–367

    Article  CAS  PubMed  Google Scholar 

  36. Moreno L, Bautista F, Ashley S, Duncan C, Zacharoulis S (2010) Does chemotherapy affect the visual outcome in children with optic pathway glioma? A systematic review of the evidence. Eur J Cancer 46:2253–2259

    Article  PubMed  Google Scholar 

  37. Ater JL, Xia C, Mazewski CM, Booth TN, Freyer DR, Packer RJ, Sposto R, Vezina G, Pollack IF (2016) Nonrandomized comparison of neurofibromatosis type 1 and non-neurofibromatosis type 1 children who received carboplatin and vincristine for progressive low-grade glioma: a report from the Children’s Oncology Group. Cancer 122:1928–1936

    Article  CAS  PubMed  Google Scholar 

  38. Lassaletta A, Scheinemann K, Zelcer SM, Hukin J, Wilson BA, Jabado N, Carret AS, Lafay-Cousin L, Larouche V, Hawkins CE, Pond GR, Poskitt K, Keene D, Johnston DL, Eisenstat DD, Krishnatry R, Mistry M, Arnoldo A, Ramaswamy V, Huang A, Bartels U, Tabori U, Bouffet E (2016) Phase II weekly vinblastine for chemotherapy-naive children with progressive low-grade glioma: a Canadian Pediatric Brain Tumor Consortium Study. J Clin Oncol 34:3537–3543

    Article  CAS  PubMed  Google Scholar 

  39. Packer RJ, Jakacki R, Horn M, Rood B, Vezina G, MacDonald T, Fisher MJ, Cohen B (2009) Objective response of multiply recurrent low-grade gliomas to bevacizumab and irinotecan. Pediatr Blood Cancer 52:791–795

    Article  PubMed  Google Scholar 

  40. Bennebroek CA, Schouten CR, Montauban-van Swijndregt MC, Saeed P, Porro GL, Pott JWR, Dittrich ATM, Oostenbrink R, Schouten-van Meeteren AY, de Jong MC, de Graaf P (2024) Treatment evaluation by volumetric segmentation in pediatric optic pathway glioma: evaluation of the effect of bevacizumab on intra-tumor components. J Neurooncol 166:79–87

    Article  CAS  PubMed  Google Scholar 

  41. Gururangan S, Fangusaro J, Poussaint TY, McLendon RE, Onar-Thomas A, Wu S, Packer RJ, Banerjee A, Gilbertson RJ, Fahey F, Vajapeyam S, Jakacki R, Gajjar A, Goldman S, Pollack IF, Friedman HS, Boyett JM, Fouladi M, Kun LE (2014) Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas–a Pediatric Brain Tumor Consortium study. Neuro Oncol 16:310–317

    Article  CAS  PubMed  Google Scholar 

  42. Siegel BI, Nelson D, Peragallo JH, MacDonald TJ, Wolf DS (2023) Visual outcomes after bevacizumab-based therapy for optic pathway glioma. Pediatr Blood Cancer 70:e30668

    Article  CAS  PubMed  Google Scholar 

  43. Green K, Panagopoulou P, D’Arco F, O’Hare P, Bowman R, Walters B, Dahl C, Jorgensen M, Patel P, Slater O, Ahmed R, Bailey S, Carceller F, Collins R, Corley E, English M, Howells L, Kamal A, Kilday JJ, Lowis S, Lumb B, Pace E, Picton S, Pizer B, Shafiq A, Uzunova L, Wayman H, Wilson S, Hargrave D, Opocher E (2023) A nationwide evaluation of bevacizumab-based treatments in pediatric low-grade glioma in the UK: safety, efficacy, visual morbidity, and outcomes. Neuro Oncol 25:774–785

    Article  CAS  PubMed  Google Scholar 

  44. Bhatia S, Chen Y, Wong FL, Hageman L, Smith K, Korf B, Cannon A, Leidy DJ, Paz A, Andress JE, Friedman GK, Metrock K, Neglia JP, Arnold M, Turcotte LM, de Blank P, Leisenring W, Armstrong GT, Robison LL, Clapp DW, Shannon K, Nakamura JL, Fisher MJ (2019) Subsequent neoplasms after a primary tumor in individuals with neurofibromatosis type 1. J Clin Oncol 37:3050–3058

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Ullrich NJ, Robertson R, Kinnamon DD, Scott RM, Kieran MW, Turner CD, Chi SN, Goumnerova L, Proctor M, Tarbell NJ, Marcus KJ, Pomeroy SL (2007) Moyamoya following cranial irradiation for primary brain tumors in children. Neurology 68:932–938

    Article  CAS  PubMed  Google Scholar 

  46. Plotkin SR, Blakeley JO, Dombi E, Fisher MJ, Hanemann CO, Walsh KS, Wolters PL, Widemann BC (2013) Achieving consensus for clinical trials: the REiNS International Collaboration. Neurology 81:S1-5

    Article  PubMed  PubMed Central  Google Scholar 

  47. Banerjee A, Jakacki RI, Onar-Thomas A, Wu S, Nicolaides T, Young Poussaint T, Fangusaro J, Phillips J, Perry A, Turner D, Prados M, Packer RJ, Qaddoumi I, Gururangan S, Pollack IF, Goldman S, Doyle LA, Stewart CF, Boyett JM, Kun LE, Fouladi M (2017) A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study. Neuro Oncol 19:1135–1144

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Gross AM, Wolters PL, Dombi E, Baldwin A, Whitcomb P, Fisher MJ, Weiss B, Kim A, Bornhorst M, Shah AC, Martin S, Roderick MC, Pichard DC, Carbonell A, Paul SM, Therrien J, Kapustina O, Heisey K, Clapp DW, Zhang C, Peer CJ, Figg WD, Smith M, Glod J, Blakeley JO, Steinberg SM, Venzon DJ, Doyle LA, Widemann BC (2020) Selumetinib in children with inoperable plexiform neurofibromas. N Engl J Med 382:1430–1442

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Fangusaro J, Onar-Thomas A, Young Poussaint T, Wu S, Ligon AH, Lindeman N, Banerjee A, Packer RJ, Kilburn LB, Goldman S, Pollack IF, Qaddoumi I, Jakacki RI, Fisher PG, Dhall G, Baxter P, Kreissman SG, Stewart CF, Jones DTW, Pfister SM, Vezina G, Stern JS, Panigrahy A, Patay Z, Tamrazi B, Jones JY, Haque SS, Enterline DS, Cha S, Fisher MJ, Doyle LA, Smith M, Dunkel IJ, Fouladi M (2019) Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial. Lancet Oncol 20:1011–1022

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. de Blank PMK, Gross AM, Akshintala S, Blakeley JO, Bollag G, Cannon A, Dombi E, Fangusaro J, Gelb BD, Hargrave D, Kim A, Klesse LJ, Loh M, Martin S, Moertel C, Packer R, Payne JM, Rauen KA, Rios JJ, Robison N, Schorry EK, Shannon K, Stevenson DA, Stieglitz E, Ullrich NJ, Walsh KS, Weiss BD, Wolters PL, Yohay K, Yohe ME, Widemann BC, Fisher MJ (2022) MEK inhibitors for neurofibromatosis type 1 manifestations: clinical evidence and consensus. Neuro Oncol 24:1845–1856

    Article  PubMed  PubMed Central  Google Scholar 

  51. Ullrich NJ, Prabhu SP, Reddy AT, Fisher MJ, Packer R, Goldman S, Robison NJ, Gutmann DH, Viskochil DH, Allen JC, Korf B, Cantor A, Cutter G, Thomas C, Perentesis JP, Mizuno T, Vinks AA, Manley PE, Chi SN, Kieran MW (2020) A phase II study of continuous oral mTOR inhibitor everolimus for recurrent, radiographic-progressive neurofibromatosis type 1-associated pediatric low-grade glioma: a Neurofibromatosis Clinical Trials Consortium study. Neuro Oncol 22:1527–1535

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Karajannis MA, Legault G, Fisher MJ, Milla SS, Cohen KJ, Wisoff JH, Harter DH, Goldberg JD, Hochman T, Merkelson A, Bloom MC, Sievert AJ, Resnick AC, Dhall G, Jones DT, Korshunov A, Pfister SM, Eberhart CG, Zagzag D, Allen JC (2014) Phase II study of sorafenib in children with recurrent or progressive low-grade astrocytomas. Neuro Oncol 16:1408–1416

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Tsuji G, Takai-Yumine A, Kato T, Furue M (2021) Metalloproteinase 1 downregulation in neurofibromatosis 1: therapeutic potential of antimalarial hydroxychloroquine and chloroquine. Cell Death Dis 12:513

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Guo X, Pan Y, Xiong M, Sanapala S, Anastasaki C, Cobb O, Dahiya S, Gutmann DH (2020) Midkine activation of CD8(+) T cells establishes a neuron-immune-cancer axis responsible for low-grade glioma growth. Nat Commun 11:2177

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Guo X, Pan Y, Gutmann DH (2019) Genetic and genomic alterations differentially dictate low-grade glioma growth through cancer stem cell-specific chemokine recruitment of T cells and microglia. Neuro Oncol 21:1250–1262

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. de Andrade Costa A, Chatterjee J, Cobb O, Cordell E, Chao A, Schaeffer S, Goldstein A, Dahiya S, Gutmann DH (2022) Immune deconvolution and temporal mapping identifies stromal targets and developmental intervals for abrogating murine low-grade optic glioma formation. Neurooncol Adv 4:vdab194

    Google Scholar 

  57. Chatterjee J, Sanapala S, Cobb O, Bewley A, Goldstein AK, Cordell E, Ge X, Garbow JR, Holtzman MJ, Gutmann DH (2021) Asthma reduces glioma formation by T cell decorin-mediated inhibition of microglia. Nat Commun 12:7122

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Hartman LL, Crawford JR, Makale MT, Milburn M, Joshi S, Salazar AM, Hasenauer B, VandenBerg SR, MacDonald TJ, Durden DL (2014) Pediatric phase II trials of poly-ICLC in the management of newly diagnosed and recurrent brain tumors. J Pediatr Hematol Oncol 36:451–457

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Anastasaki C, Mo J, Chen JK, Chatterjee J, Pan Y, Scheaffer SM, Cobb O, Monje M, Le LQ, Gutmann DH (2022) Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1. Nat Commun 13:2785

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Pan Y, Hysinger JD, Barron T, Schindler NF, Cobb O, Guo X, Yalcin B, Anastasaki C, Mulinyawe SB, Ponnuswami A, Scheaffer S, Ma Y, Chang KC, Xia X, Toonen JA, Lennon JJ, Gibson EM, Huguenard JR, Liau LM, Goldberg JL, Monje M, Gutmann DH (2021) NF1 mutation drives neuronal activity-dependent initiation of optic glioma. Nature 594:277–282

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Monje M, Borniger JC, D’Silva NJ, Deneen B, Dirks PB, Fattahi F, Frenette PS, Garzia L, Gutmann DH, Hanahan D, Hervey-Jumper SL, Hondermarck H, Hurov JB, Kepecs A, Knox SM, Lloyd AC, Magnon C, Saloman JL, Segal RA, Sloan EK, Sun X, Taylor MD, Tracey KJ, Trotman LC, Tuveson DA, Wang TC, White RA, Winkler F (2020) Roadmap for the emerging field of cancer neuroscience. Cell 181:219–222

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Omrani A, van der Vaart T, Mientjes E, van Woerden GM, Hojjati MR, Li KW, Gutmann DH, Levelt CN, Smit AB, Silva AJ, Kushner SA, Elgersma Y (2015) HCN channels are a novel therapeutic target for cognitive dysfunction in neurofibromatosis type 1. Mol Psychiatry 20:1311–1321

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Robison N, Pauly J, Malvar J, Gardner S, Allen J, Margol A, MacDonald T, Bendel A, Kilburn L, Cluster A, Bowers D, Dorris K, Ullrich N, De Mola RL, Alva E, Leary S, Baxter P, Khatib Z, Cohen K, Davidson TB, Plant A, Bandopadhayay P, Stopka S, Agar N, Wright K, Nelson M, Chi Y-Y, Kieran M (2022) LTBK-04. LATE BREAKING ABSTRACT: MEK162 (binimetinib) in children with progressive or recurrent low-grade glioma: a multi-institutional phase II and target validation study. Neuro Oncol 24:i191–i192

    Article  PubMed Central  Google Scholar 

  64. Perreault S, Kiaei DS, Dehaes M, Larouche V, Tabori U, Hawkin C, Lippé S, Ellezam B, Cantin E, Routhier M-È, Caru M, Vairy S, Legault G, Bouffet E, Ramaswamy V, Coltin H, Lafay-Cousin L, Hukin J, Erker C, Jabado N, Team T-S (2022) A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK/ERK pathway. J Clin Oncol 40:2042–2042

    Article  Google Scholar 

  65. Vinitsky A, Chiang J, Bag AK, Campagne O, Stewart CF, Dunphy P, Shulkin B, Li Q, Lin T, Hoehn ME, Johnson JN, Towbin JA, Khan R, Tatevossian RG, Armstrong GT, Potter B, Conklin H, Shearer T, Scott S, Robinson GW (2022) LGG-22. SJ901: phase I/II evaluation of single agent mirdametinib (PD-0325901), a brain-penetrant MEK1/2 inhibitor, for the treatment of children, adolescents, and young adults with low-grade glioma (LGG). Neuro Oncol 24:i92

    Article  PubMed Central  Google Scholar 

Download references

Funding

There is no relevant funding for the preparation of this manuscript.

Author information

Authors and Affiliations

  1. Division of Oncology, Children’s Hospital of Philadelphia, 3500 Civic Center Blvd, Philadelphia, PA, 19104, USA

    Chelsea Kotch & Michael J. Fisher

  2. Department of Pediatrics, University of Pennsylvania Perelman School of Medicine, 3500 Civic Center Blvd, Philadelphia, PA, 19104, USA

    Chelsea Kotch & Michael J. Fisher

  3. Division of Oncology, University of Cincinnati Medical Center and Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, USA

    Peter de Blank

  4. Division of Neurology, Washington University of St. Louis, St. Louis, MO, USA

    David H. Gutmann

Authors
  1. Chelsea Kotch
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peter de Blank
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. David H. Gutmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Michael J. Fisher
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

The literature search and first draft of the manuscript was written by C.K. C.K. prepared the figure and tables. All authors (C.K., P.D.B., D.H.G., and M.J.F.) read, edited, and approved the final manuscript.

Corresponding author

Correspondence to Chelsea Kotch.

Ethics declarations

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kotch, C., de Blank, P., Gutmann, D.H. et al. Low-grade glioma in children with neurofibromatosis type 1: surveillance, treatment indications, management, and future directions. Childs Nerv Syst (2024). https://doi.org/10.1007/s00381-024-06430-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s00381-024-06430-8

Keywords

Search

Navigation